Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
2 other identifiers
observational
20,000
1 country
9
Brief Summary
An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2022
Longer than P75 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 29, 2022
CompletedFirst Submitted
Initial submission to the registry
May 7, 2024
CompletedFirst Posted
Study publicly available on registry
May 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2031
ExpectedMay 16, 2024
May 1, 2024
2.6 years
May 7, 2024
May 11, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Enrolled Patients
Total number of patients with pediatric rheumatic and immunologic diseases enrolled in the registry
up to 10 years
Secondary Outcomes (4)
Physician Global Assessment
up to 10 years
Patient or Parent Global Assessment
up to 10 years
Proportion of Participants with Clinically Inactive Disease
up to 10 years
Childhood Health Assessment Questionnaire (CHAQ)
up to 10 years
Eligibility Criteria
Chinese children with pediatric rheumatic and immunologic diseases enrolled from CAPRID centers.
You may qualify if:
- Age \<= 18 years old
- Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity)
- Diagnosed and Treated in China
You may not qualify if:
- Disagreement of involving in this study by the patient or his/her family.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Peking Union Medical College Hospitallead
- Children's Hospital of Chongqing Medical Universitycollaborator
- Central South Universitycollaborator
- Beijing Children's Hospitalcollaborator
- Shenzhen Children's Hospitalcollaborator
- Children's Hospital of Nanjing Medical Universitycollaborator
- The University of Hong Kongcollaborator
- Zhejiang Universitycollaborator
- Third Hospital of Peking Universitycollaborator
Study Sites (9)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Third Hospital of Peking University
Beijing, Beijing Municipality, China
Chidren's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Shenzhen Children's Hospital
Shenzhen, Guangdong, China
The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI)
Shenzhen, Guangdong, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Children's Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hongmei Song, MD
Peking Union Medical College Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
May 7, 2024
First Posted
May 16, 2024
Study Start
April 29, 2022
Primary Completion
November 30, 2024
Study Completion (Estimated)
December 31, 2031
Last Updated
May 16, 2024
Record last verified: 2024-05